1. Regulation of PD-L1 expression in non-small cell lung cancer by interleukin-1b.
- Author
-
Aiko Hirayama, Kentaro Tanaka, Hirono Tsutsumi, Takayuki Nakanishi, Sho Yamashita, Shun Mizusaki, Yumiko Ishii, Keiichi Ota, Yasuto Yoneshima, Eiji Iwama, and Isamu Okamoto
- Subjects
NON-small-cell lung carcinoma ,GENE expression ,PROGRAMMED death-ligand 1 ,TRANSCRIPTION factors ,MITOGEN-activated protein kinases ,IMMUNE checkpoint inhibitors - Abstract
Introduction: Programmed cell death-ligand 1 (PD-L1) is a biomarker for prediction of the clinical efficacy of immune checkpoint inhibitors in various cancer types. The role of cytokines in regulation of PD-L1 expression in tumor cells has not been fully characterized, however. Here we show that interleukin-1b (IL-1b) plays a key role in regulation of PD-L1 expression in non-small cell lung cancer (NSCLC). Methods: We performed comprehensive screening of cytokine gene expression in NSCLC tissue using available single-cell RNA-Sequence data. Then we examined the role of IL-1b in vitro to elucidate its induction of PD-L1 on NSCLC cells. Results: The IL-1b gene is highly expressed in the tumor microenvironment, particularly in macrophages. The combination of IL-1b and interferon-g (IFN-g) induced a synergistic increase in PD-L1 expression in NSCLC cell lines. IL-1b and IFN-g also cooperatively activated mitogen-activated protein kinase (MAPK) signaling and promoted the binding of downstream transcription factors to the PD-L1 gene promoter. Furthermore, inhibitors of MAPK signaling blocked upregulation of PD-L1 by IL-1b and IFN-g. Discussion:Our study reports high levels of IL-1b in the tumor microenvironment may cooperate with IFN-g to induce maximal PD-L1 expression in tumor cells via activation of MAPK signaling, with the IL-1b-MAPK axis being a promising therapeutic target for attenuation of PD-L1-mediated suppression of antitumor immunity. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF